Novartis AG
SIX:NOVN
Novartis AG
SIX:NOVN
Price:
120.24
CHF
-1.26%
Market Cap:
CHf230.7B
Relative Value
The Relative Value of one
NOVN
stock under the Base Case scenario is
105.21
CHF.
Compared to the current market price of 120.24 CHF,
Novartis AG
is
Overvalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOVN
Relative Value
Base Case
105.21
CHF
Overvaluation 13%
Multiples Across Competitors
NOVN Competitors Multiples
Novartis AG Competitors
Novartis AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF | 5.3 | 21.3 | 13.2 | 16.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.6 | 7.8 | 9.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
81.7B GBP | 2.5 | 14.2 | 7.9 | 9.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
